These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 31434968)

  • 1. Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR.
    Vigón L; Vázquez-Morón S; Berenguer J; González-García J; Jiménez-Sousa MÁ; Guardiola JM; Crespo M; de Los Santos I; Von Wichmann MA; Carrero A; Yélamos MB; Gómez J; Resino S; Martínez I;
    Sci Rep; 2019 Aug; 9(1):12163. PubMed ID: 31434968
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies in patients with chronic hepatitis C, genotype 1, against a panel of genotype 1 culture viruses: lack of correlation to treatment outcome.
    Pedersen J; Jensen TB; Carlsen TH; Schønning K; Christensen PB; Laursen AL; Krarup H; Bukh J; Weis N
    PLoS One; 2013; 8(5):e62674. PubMed ID: 23667506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The IL28B effect on hepatitis C virus kinetics among HIV patients after the first weeks of pegylated-interferon/ribavirin treatment varies according to hepatitis C virus-1 subtype.
    Rivero-Juarez A; Lopez-Cortes LF; Camacho A; Caruz A; Torres-Cornejo A; Martinez-Dueñas L; Ruiz-Valderas R; Torre-Cisneros J; Gutierrez-Valencia A; Rivero A
    AIDS; 2013 Jul; 27(12):1941-7. PubMed ID: 23917425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response predictors and clinical benefits of hepatitis C retreatment with pegylated interferon and ribavirin in HIV/HCV coinfection.
    Peribañez-Gonzalez M; da Silva MH; Vilar FC; Seixas-Santos Nastri AC; Ferreira PA; Focaccia R; Mendes Correa MC
    Ann Hepatol; 2013; 12(2):228-35. PubMed ID: 23396734
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin.
    Laguno M; Larrousse M; Murillas J; Blanco JL; León A; Milinkovic A; Loncá M; Martinez E; Sánchez-Tapias JM; de Lazzari E; Gatell JM; Costa J; Mallolas J
    J Acquir Immune Defic Syndr; 2007 Feb; 44(2):174-8. PubMed ID: 17106276
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Analysis of neutralizing antibodies against hepatitis C virus in patients who were treated with pegylated-interferon plus ribavirin.
    Sasayama M; Deng L; Kim SR; Ide Y; Shoji I; Hotta H
    Kobe J Med Sci; 2010 Sep; 56(2):E60-6. PubMed ID: 21063147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.
    Gottwein JM; Scheel TK; Callendret B; Li YP; Eccleston HB; Engle RE; Govindarajan S; Satterfield W; Purcell RH; Walker CM; Bukh J
    J Virol; 2010 May; 84(10):5277-93. PubMed ID: 20200247
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of peg-IFN alfa-2a with ribavirin for the treatment of HCV/HIV coinfected patients who failed previous IFN based therapy.
    Rodríguez-Torres M; Rodríguez-Orengo JF; Ríos-Bedoya CF; Fernández-Carbia A; González-Lassalle E; Salgado-Mercado R; Marxuach-Cuétara AM
    J Clin Virol; 2007 Jan; 38(1):32-8. PubMed ID: 17064957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained virological response according to the type of early virological response in HCV and HCV/HIV.
    Lerias de Almeida PR; Alves de Mattos A; Valle Tovo C
    Ann Hepatol; 2010; 9(2):150-5. PubMed ID: 20526007
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.
    Pineda JA; Mira JA; Gil Ide L; Valera-Bestard B; Rivero A; Merino D; Girón-González JA; Ríos-Villegas MJ; González-Serrano M; Collado A; García-García JA; Carrillo-Gómez R; López-Cortés LF; Gómez-Mateos J
    J Antimicrob Chemother; 2007 Dec; 60(6):1347-54. PubMed ID: 17938129
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Negative impact of HIV infection on broad-spectrum anti-HCV neutralizing antibody titers in HCV-infected patients with advanced HCV-related cirrhosis.
    Sepúlveda-Crespo D; Yélamos MB; Díez C; Gómez J; Hontañón V; Torresano-Felipe F; Berenguer J; González-García J; Ibañez-Samaniego L; Llop E; Olveira A; Martínez J; Resino S; Martínez I
    Biomed Pharmacother; 2022 Jun; 150():113024. PubMed ID: 35483197
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Response to pegylated interferon plus ribavirin among HIV/hepatitis C virus-coinfected patients with compensated liver cirrhosis.
    Mira JA; García-Rey S; Rivero A; de los Santos-Gil I; López-Cortés LF; Girón-González JA; Téllez F; Márquez M; Merino D; Ríos-Villegas MJ; Macías J; Rivero-Juárez A; Pineda JA
    Clin Infect Dis; 2012 Dec; 55(12):1719-26. PubMed ID: 22955435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insulin resistance impairs response to interferon plus ribavirin in patients coinfected with HIV and hepatitis C virus.
    Ryan P; Resino S; Miralles P; Cosín J; López JC; Moreno S; Catalán P; Ramírez M; Gutiérrez I; Berenguer J
    J Acquir Immune Defic Syndr; 2010 Oct; 55(2):176-81. PubMed ID: 20577091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid virological response at week 4 predicts response to pegylated interferon plus ribavirin among HIV/HCV-coinfected patients.
    Mira JA; Valera-Bestard B; Arizcorreta-Yarza A; González-Serrano M; Torre-Cisneros J; Santos I; Vergara S; Gutiérrez-Valencia A; Girón-González JA; Macías J; López-Cortés LF; Pineda JA
    Antivir Ther; 2007; 12(4):523-9. PubMed ID: 17668561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breadth of neutralization and synergy of clinically relevant human monoclonal antibodies against HCV genotypes 1a, 1b, 2a, 2b, 2c, and 3a.
    Carlsen TH; Pedersen J; Prentoe JC; Giang E; Keck ZY; Mikkelsen LS; Law M; Foung SK; Bukh J
    Hepatology; 2014 Nov; 60(5):1551-62. PubMed ID: 25043937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinical efficacy of pegylated interferon in patients co-infected with HIV and HCV who failed standard interferon therapy].
    Ke YC; Li LH; Hu FY; He Y; Lan Y; Chen XJ; Tang XP; Cai WP
    Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):181-5. PubMed ID: 27095760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatitis C virus-RNA clearance in HIV-coinfected patients with chronic hepatitis C treated with pegylated interferon plus ribavirin.
    Soriano V; Núñez M; Camino N; Maida I; Barreiro P; Romero M; Martin-Carbonero L; Garcia-Samaniego J; González-Lahoz J
    Antivir Ther; 2004 Aug; 9(4):505-9. PubMed ID: 15456081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.